<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: operations", fill: "#006a4e"},
{source: "4: operations", target: "4: products may", fill: "#006a4e"},
{source: "4: products may", target: "4: product liability", fill: "#006a4e"},
{source: "4: operations", target: "9: Substantially ", fill: "#ff5a36"},
{source: "9: Substantially ", target: "9: backed by", fill: "#ff5a36"},
{source: "9: backed by", target: "9: returns due", fill: "#ff5a36"},
{source: "9: Substantially ", target: "13: substantially", fill: "#c0c"},
{source: "13: substantially", target: "13: sterilized by", fill: "#c0c"},
{source: "13: substantially", target: "14: manufactured", fill: "#8878c3"},
{source: "14: manufactured", target: "14: by third parties", fill: "#8878c3"},
{source: "14: manufactured", target: "17: proprietary technology", fill: "#00ff7f"},
{source: "17: proprietary technology", target: "17: may infringe on", fill: "#00ff7f"},
{source: "17: proprietary technology", target: "18: remain competitive", fill: "#e6e200"},
{source: "18: remain competitive", target: "18: dependent", fill: "#e6e200"},
{source: "18: dependent", target: "18: companies from using", fill: "#e6e200"},
{source: "18: companies from using", target: "18: proprietary technology incorporated", fill: "#e6e200"},
{source: "18: remain competitive", target: "20: unable however", fill: "#8a496b"},
{source: "20: unable however", target: "20: prevent others", fill: "#8a496b"},
{source: "20: prevent others", target: "20: proprietary", fill: "#8a496b"},
{source: "20: proprietary", target: "20: numerous reasons", fill: "#8a496b"},
{source: "20: numerous reasons", target: "20: Companys ", fill: "#8a496b"},
{source: "20: Companys ", target: "20: operations", fill: "#8a496b"},
{source: "20: operations", target: "20: financial condition", fill: "#8a496b"},
{source: "20: financial condition", target: "20: issued patents may", fill: "#8a496b"},
{source: "20: issued patents may", target: "20: sufficiently broad", fill: "#8a496b"},
{source: "20: sufficiently broad", target: "20: from copying", fill: "#8a496b"},
{source: "20: from copying", target: "20: proprietary technologies", fill: "#8a496b"},
{source: "20: proprietary technologies", target: "20: technologies", fill: "#8a496b"},
{source: "20: technologies", target: "20: challenged by third parties", fill: "#8a496b"},
{source: "20: challenged by third parties", target: "20: products may infringe on", fill: "#8a496b"},
{source: "20: products may infringe on", target: "20: discontinue", fill: "#8a496b"},
{source: "20: discontinue", target: "20: manufacture", fill: "#8a496b"},
{source: "20: manufacture", target: "20: such products", fill: "#8a496b"},
{source: "20: such products", target: "20: associated with seeking enforcement", fill: "#8a496b"},
{source: "20: associated with seeking enforcement", target: "20: patents against", fill: "#8a496b"},
{source: "20: patents against", target: "20: infringement", fill: "#8a496b"},
{source: "20: infringement", target: "20: defending four self against allegations", fill: "#8a496b"},
{source: "20: defending four self against allegations", target: "20: significant", fill: "#8a496b"},
{source: "20: significant", target: "20: pending patent applications may", fill: "#8a496b"},
{source: "20: pending patent applications may", target: "20: conflict with", fill: "#8a496b"},
{source: "20: conflict with", target: "20: existing patent", fill: "#8a496b"},
{source: "20: existing patent", target: "20: persons may independently", fill: "#8a496b"},
{source: "20: unable however", target: "26: acquisition", fill: "#fae7b5"},
{source: "26: acquisition", target: "26: additional", fill: "#fae7b5"},
{source: "26: additional", target: "26: challenges", fill: "#fae7b5"},
{source: "26: challenges", target: "26: integrating", fill: "#fae7b5"},
{source: "26: integrating", target: "26: operations", fill: "#fae7b5"},
{source: "26: operations", target: "26: informational", fill: "#fae7b5"},
{source: "26: informational", target: "26: management", fill: "#fae7b5"},
{source: "26: management", target: "26: characteristics with", fill: "#fae7b5"},
{source: "26: acquisition", target: "29: adequately", fill: "#ffdead"},
{source: "29: adequately", target: "29: manage issues", fill: "#ffdead"},
{source: "29: manage issues", target: "29: future acquisitions", fill: "#ffdead"},
{source: "29: future acquisitions", target: "29: such acquisitions may", fill: "#ffdead"},
{source: "29: such acquisitions may", target: "29: negative adverse", fill: "#ffdead"},
{source: "29: adequately", target: "30: significant adverse", fill: "#796878"},
{source: "30: significant adverse", target: "30: comply with governing", fill: "#796878"},
{source: "30: comply with governing", target: "30: regulations could adversely affect", fill: "#796878"},
{source: "30: significant adverse", target: "31: Substantially ", fill: "#ff004f"},
{source: "31: Substantially ", target: "31: devices as defined", fill: "#ff004f"},
{source: "31: devices as defined", target: "31: manufacture distribution", fill: "#ff004f"},
{source: "31: manufacture distribution", target: "31: advertisement", fill: "#ff004f"},
{source: "31: advertisement", target: "31: regulation by", fill: "#ff004f"},
{source: "31: regulation by", target: "31: FDA in the United States ", fill: "#ff004f"},
{source: "31: FDA in the United States ", target: "31: regulatory", fill: "#ff004f"},
{source: "31: regulatory", target: "31: manufactured", fill: "#ff004f"},
{source: "31: manufactured", target: "31: distributed", fill: "#ff004f"},
{source: "31: Substantially ", target: "33: export control restrictions governed by", fill: "#a76bcf"},
{source: "33: export control restrictions governed by", target: "33: US Department of the Treasury ", fill: "#a76bcf"},
{source: "33: US Department of the Treasury ", target: "33: regulatory", fill: "#a76bcf"},
{source: "33: export control restrictions governed by", target: "34: operations", fill: "#c66"},
{source: "34: operations", target: "34: financial condition could", fill: "#c66"},
{source: "34: financial condition could", target: "34: adversely affected", fill: "#c66"},
{source: "34: adversely affected", target: "34: compliance with governing regulations", fill: "#c66"},
{source: "34: operations", target: "35: such regulations", fill: "#aa4069"},
{source: "35: such regulations", target: "35: restrictive", fill: "#aa4069"},
{source: "35: restrictive", target: "35: comply with", fill: "#aa4069"},
{source: "35: comply with", target: "35: could adversely affect", fill: "#aa4069"},
{source: "35: could adversely affect", target: "35: operations", fill: "#aa4069"},
{source: "35: operations", target: "35: financial condition", fill: "#aa4069"},
{source: "35: such regulations", target: "36: significant", fill: "#f3e5ab"},
{source: "36: significant", target: "36: derived from", fill: "#f3e5ab"},
{source: "36: derived from", target: "36: few products", fill: "#f3e5ab"},
{source: "36: significant", target: "37: significant", fill: "#e49b0f"},
{source: "37: significant", target: "37: attributable", fill: "#e49b0f"},
{source: "37: attributable", target: "37: inflation devices", fill: "#e49b0f"},
{source: "37: significant", target: "41: subsequent developments", fill: "#96c"},
{source: "41: subsequent developments", target: "41: medical technology", fill: "#96c"},
{source: "41: medical technology", target: "41: methodology", fill: "#96c"},
{source: "41: methodology", target: "41: deteriorating financial performance", fill: "#96c"},
{source: "41: subsequent developments", target: "49: market price", fill: "#fdee00"},
{source: "49: market price", target: "49: common stock", fill: "#fdee00"},
{source: "49: common stock", target: "49: may continue", fill: "#fdee00"},
{source: "49: market price", target: "50: market price", fill: "#ff3800"},
{source: "50: market price", target: "50: common stock", fill: "#ff3800"},
{source: "50: common stock", target: "50: may continue", fill: "#ff3800"},
{source: "50: may continue", target: "50: highly volatile", fill: "#ff3800"},
{source: "50: highly volatile", target: "50: various reasons", fill: "#ff3800"},
{source: "50: various reasons", target: "50: following which could", fill: "#ff3800"},
{source: "50: following which could", target: "50: Companys ", fill: "#ff3800"},
{source: "50: Companys ", target: "50: operations", fill: "#ff3800"},
{source: "50: operations", target: "50: announcement", fill: "#ff3800"},
{source: "50: announcement", target: "50: technical innovations", fill: "#ff3800"},
{source: "50: technical innovations", target: "50: announcements by", fill: "#ff3800"},
{source: "50: announcements by", target: "50: competitors", fill: "#ff3800"},
{source: "50: competitors", target: "50: Development ", fill: "#ff3800"},
{source: "50: Development ", target: "50: technology", fill: "#ff3800"},
{source: "50: technology", target: "50: Claims ", fill: "#ff3800"},
{source: "50: Claims ", target: "50: potential infringement", fill: "#ff3800"},
{source: "50: potential infringement", target: "50: intellectual property rights", fill: "#ff3800"},
{source: "50: intellectual property rights", target: "50: Analysts ", fill: "#ff3800"},
{source: "50: Analysts ", target: "50: projections", fill: "#ff3800"},
{source: "50: projections", target: "50: recommendations", fill: "#ff3800"},
{source: "50: recommendations", target: "50: medical technology stocks generally", fill: "#ff3800"},
{source: "50: medical technology stocks generally", target: "50: generally", fill: "#ff3800"},
{source: "50: generally", target: "50: restatement", fill: "#ff3800"},
{source: "50: restatement", target: "50: financial statements", fill: "#ff3800"},
{source: "50: financial statements", target: "50: investigation", fill: "#ff3800"},
{source: "50: investigation", target: "50: regulatory authority", fill: "#ff3800"},
{source: "50: regulatory authority", target: "50: general decline", fill: "#ff3800"},
{source: "50: general decline", target: "50: stock prices", fill: "#ff3800"},
{source: "50: stock prices", target: "50: capital markets", fill: "#ff3800"},
{source: "50: market price", target: "52: Fluctuations ", fill: "#faebd7"},
{source: "52: Fluctuations ", target: "52: exchange between", fill: "#faebd7"},
{source: "52: exchange between", target: "52: Euro and GBP ", fill: "#faebd7"},
{source: "52: Euro and GBP ", target: "52: negative impact on", fill: "#faebd7"},
{source: "52: Fluctuations ", target: "53: exchange rate between", fill: "#30ba8f"},
{source: "53: exchange rate between", target: "53: Euro and the US Dollar ", fill: "#30ba8f"},
{source: "53: exchange rate between", target: "54: December ", fill: "#0f0"},
{source: "54: December ", target: "54: denominated", fill: "#0f0"},
{source: "54: denominated", target: "54: the Euro and the GBP ", fill: "#0f0"},
{source: "54: the Euro and the GBP ", target: "54: declines against", fill: "#0f0"},
{source: "54: declines against", target: "54: whose prices", fill: "#0f0"},
{source: "54: whose prices", target: "54: enter into hedging transactions which could mitigate", fill: "#0f0"},
{source: "54: enter into hedging transactions which could mitigate", target: "54: declining exchange rates", fill: "#0f0"},
{source: "54: December ", target: "59: Lampropoulos ", fill: "#de3163"},
{source: "59: Lampropoulos ", target: "59: agreement prohibiting", fill: "#de3163"},
{source: "59: agreement prohibiting", target: "59: departure", fill: "#de3163"},
{source: "59: departure", target: "59: key man life insurance on", fill: "#de3163"},
{source: "59: Lampropoulos ", target: "65: depend on thirdparty", fill: "#c8a2c8"},
{source: "65: depend on thirdparty", target: "65: transportation companies", fill: "#c8a2c8"},
{source: "65: transportation companies", target: "65: supplies necessary", fill: "#c8a2c8"},
{source: "65: supplies necessary", target: "65: manufacture", fill: "#c8a2c8"},
{source: "65: manufacture", target: "65: Merit ", fill: "#c8a2c8"},
{source: "65: Merit ", target: "65: various facilities", fill: "#c8a2c8"},
{source: "65: various facilities", target: "65: subsidiaries located worldwide", fill: "#c8a2c8"},
{source: "65: depend on thirdparty", target: "66: manufacturing operations", fill: "#967117"},
{source: "66: manufacturing operations", target: "66: operations", fill: "#967117"},
{source: "66: operations", target: "66: transportation companies", fill: "#967117"},
{source: "66: transportation companies", target: "66: depend may", fill: "#967117"},
{source: "66: depend may", target: "66: adversely affected by natural disasters", fill: "#967117"},
{source: "66: adversely affected by natural disasters", target: "66: significant human events such as", fill: "#967117"},
{source: "66: significant human events such as", target: "66: war terrorist attack riot strike", fill: "#967117"},
{source: "66: manufacturing operations", target: "68: on reimbursement imposed by governmental", fill: "#f4bbff"},
{source: "68: on reimbursement imposed by governmental", target: "68: programs may", fill: "#f4bbff"},
{source: "68: programs may", target: "68: adversely affect", fill: "#f4bbff"},
{source: "68: on reimbursement imposed by governmental", target: "71: addition limitations on reimbursement", fill: "#c72"},
{source: "71: addition limitations on reimbursement", target: "71: procedures which utilize", fill: "#c72"},
{source: "71: procedures which utilize", target: "71: products could adversely affect sales", fill: "#c72"},
{source: "71: addition limitations on reimbursement", target: "START_HERE", fill: "#c72"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Oil and Gas Storage and Transportation</td>
    </tr>
    <tr>
      <td>Oil and Gas Refining and Marketing and Transportation</td>
    </tr>
    <tr>
      <td>Transportation</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cross_product">Cross product</a></td>
      <td>In mathematics, the cross product or vector product (occasionally directed area product, to emphasize its geometric significance) is a binary operation on two vectors in a three-dimensional oriented  Euclidean vector space (named here \n  \n    \n      \n        E\n      \n    \n    {\displaystyle E}\n  ), and is denoted by the symbol \n  \n    \n      \n        ×\n      \n    \n    {\displaystyle \times }\n  . Given two linearly independent vectors a and b, the cross product, a × b (read "a cross b"), is a vector that is perpendicular to both a and b, and thus normal to the plane containing them.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Back_to_the_Future">Back to the Future</a></td>
      <td>Back to the Future is a 1985 American science fiction film directed by Robert Zemeckis, and written by Zemeckis and Bob Gale. It stars Michael J. Fox, Christopher Lloyd, Lea Thompson, Crispin Glover, and Thomas F. Wilson.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sterilization_(microbiology)">Sterilization (microbiology)</a></td>
      <td>Sterilization refers to any process that removes, kills, or deactivates all forms of life (particularly microorganisms such as fungi, bacteria, spores, and unicellular eukaryotic organisms) and other biological agents such as prions present in or on a specific surface, object, or fluid. Sterilization can be achieved through various means, including heat, chemicals, irradiation, high pressure, and filtration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Third_party_(United_States)">Third party (United States)</a></td>
      <td>Third party is a term used in the United States for American political parties other than the two dominant parties, currently the Republican and Democratic Parties.  Sometimes the phrase "minor party" is used instead of third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dolby_Cinema">Dolby Cinema</a></td>
      <td>Dolby Cinema is a premium cinema  created by Dolby Laboratories that combines Dolby proprietary technologies such as Dolby Vision and Dolby Atmos, as well as other signature entrance and intrinsic design features. The technology competes with IMAX and other premium large formats such as Cinemark's XD and Regal's RPX.\n\n\n== History ==\nThe first installations featuring Dolby Cinema were JT (now Vue) Bioscopen Cinema in Eindhoven, Netherlands on 18 December 2014; followed by Cinesa La Maquinista in Barcelona, Spain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Economic_liberalization">Economic liberalization</a></td>
      <td>Economic liberalization (or economic liberalisation) is the lessening of government regulations and restrictions in an economy in exchange for greater participation by private entities. In politics, the doctrine is associated with classical liberalism and neoliberalism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dependant">Dependant</a></td>
      <td>A dependant is a person who relies on another as a primary source of income. A common-law spouse who is financially supported by their partner may also be included in this definition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_film_production_companies">List of film production companies</a></td>
      <td>This is a list of film production and distribution companies. A production company may specialize in producing their in-house films or own subsidiary development companies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aleksandar_Rakić">Aleksandar Rakić</a></td>
      <td>Aleksandar Rakić (born February 6, 1992)  is an Austrian mixed martial artist. He currently competes in the Light Heavyweight division in the Ultimate Fighting Championship (UFC).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Psychotherapy_discontinuation">Psychotherapy discontinuation</a></td>
      <td>Psychotherapy discontinuation, also known as unilateral termination, patient dropout, and premature termination, is a patient's decision to stop mental health treatment before they have received an adequate number of sessions. In the United States, the prevalence of patient dropout is estimated to be between 40–60% over the course of treatment however, the overwhelming majority of patients will drop after two sessions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Continuous_integration">Continuous integration</a></td>
      <td>In software engineering, continuous integration (CI) is the practice of merging all developers' working copies to a shared mainline several times a day. Grady Booch first proposed the term CI in his 1991 method, although he did not advocate integrating several times a day.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Library_acquisitions">Library acquisitions</a></td>
      <td>Library acquisitions is the department of a library responsible for the selection and purchase of materials or resources. The department may select vendors, negotiate consortium pricing, arrange for standing orders, and select individual titles or resources.Libraries, both physical and digital, usually have four common broad goals that help dictate these responsibilities.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dexlansoprazole">Dexlansoprazole</a></td>
      <td>Dexlansoprazole, sold under the trade name Dexilant among others, is a medication which reduces stomach acid. It is used to treat gastroesophageal reflux disease.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nash_equilibrium">Nash equilibrium</a></td>
      <td>In game theory, the Nash equilibrium, named after the mathematician John Forbes Nash Jr., is the most common way to define the solution of a non-cooperative game involving two or more players. In a Nash equilibrium, each player is assumed to know the equilibrium strategies of the other players, and no one has anything to gain by changing only one's own strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Line_regulation">Line regulation</a></td>
      <td>Line regulation is the ability of a power supply to maintain a constant output voltage despite changes to the input voltage, with the output current drawn from the power supply remaining constant.\n\n  \n    \n      \n        \n          Line Regulation\n        \n        =\n        \n          \n            \n              Δ\n              \n                V\n                \n                  o\n                \n              \n            \n            \n              Δ\n              \n                V\n                \n                  i \n                \n              \n            \n          \n        \n        ⋅\n        100\n        %\n      \n    \n    {\displaystyle {\text{Line Regulation}}={\frac {\Delta V_{\text{o}}}{\Delta V_{\text{i }}}}\cdot 100\%}\n  where ΔVi is the change in input voltage while ΔVo is the corresponding change in output voltage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Secretary_of_the_Treasury">United States Secretary of the Treasury</a></td>
      <td>The United States secretary of the treasury is the head of the United States Department of the Treasury, and is the chief financial officer of the federal government of the United States. The secretary of the treasury serves as the principal advisor to the president of the United States on all matters pertaining to economic and fiscal policy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Symbols_of_the_United_States_Department_of_the_Treasury">Symbols of the United States Department of the Treasury</a></td>
      <td>Symbols of the United States Department of the Treasury include the Flag of the Treasury Department and the U.S. Treasury Seal. The seal actually predates the department itself, having originated with the Board of Treasury during the period of the Articles of Confederation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Disease">Disease</a></td>
      <td>A disease is a particular abnormal condition that negatively affects the structure or function of all or part of an organism, and that is not immediately due to any external injury. Diseases are often known to be medical conditions that are associated with specific signs and symptoms.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Building_regulations_in_the_United_Kingdom">Building regulations in the United Kingdom</a></td>
      <td>Building regulations in the United Kingdom are statutory instruments or statutory regulations that seek to ensure that the policies set out in the relevant legislation are carried out. Building regulations approval is required for most building work in the UK. Building regulations that apply across England and Wales are set out in the Building Act 1984 while those that apply across Scotland are set out in the Building (Scotland) Act 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_sports_team_names_and_mascots_derived_from_indigenous_peoples">List of sports team names and mascots derived from indigenous peoples</a></td>
      <td>The practice of deriving sports team names, imagery, and mascots from Indigenous peoples of North America is a significant phenomenon in the United States and Canada. The popularity of the American Indian in global culture has led to a number of teams in Europe also adopting team names derived from Native Americans.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Attributable_fraction_among_the_exposed">Attributable fraction among the exposed</a></td>
      <td>In epidemiology, attributable fraction among the exposed (AFe) is the proportion of incidents in the exposed group that are attributable to the risk factor. The term attributable risk percent among the exposed is used if the fraction is expressed as a percentage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/North_South_MRT_line">North South MRT line</a></td>
      <td>The North South line (NSL) is a high-capacity Mass Rapid Transit (MRT) line in Singapore, operated by SMRT Corporation. Coloured red on the rail map, the line is 45 kilometres (28 mi) long and serves 27 stations, 11 of which, between the Bishan and Marina South Pier stations, are underground.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Naturalism_(philosophy)">Naturalism (philosophy)</a></td>
      <td>In philosophy, naturalism is the idea or belief that only natural laws and forces (as opposed to supernatural ones) operate in the universe.\n\nNaturalism is not so much a special system as a point of view or tendency common to a number of philosophical and religious systems; not so much a well-defined set of positive and negative doctrines as an attitude or spirit pervading and influencing many doctrines.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Industry_average">Industry average</a></td>
      <td>Industry averages (of financial ratios) are generally using as benchmarks or tools which helps business to make comparisons that helps to determine its position within the industry and evaluate financial performance of the business. It is a useful tool for business managers and investors, helps with decision making process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Transient_Random-Noise_Bursts_with_Announcements">Transient Random-Noise Bursts with Announcements</a></td>
      <td>Transient Random-Noise Bursts with Announcements is the second studio album by English-French rock band Stereolab. It was released on 24 August 1993 and was issued by Duophonic Records and Elektra Records.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Great_Recession">Great Recession</a></td>
      <td>The Great Recession was a period of marked general decline (recession) observed in national economies globally that occurred between 2007 and 2009. The scale and timing of the recession varied from country to country (see map).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/SBI_Capital_Markets">SBI Capital Markets</a></td>
      <td>SBI Capital Markets (SBICAPS) is a wholly owned investment banking subsidiary of State Bank of India (SBI). Headquartered in Mumbai, SBICAP has 5 regional offices across India (Ahmedabad, Chennai, Hyderabad, Kolkata and New Delhi) and 4 subsidiaries - SBICAP Securities Limited, SBICAP Trustee Company Limited, SBICAP Ventures Limited and SBICAP (Singapore) Limited.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Population_exchange_between_Poland_and_Soviet_Ukraine">Population exchange between Poland and Soviet Ukraine</a></td>
      <td>The population exchange between Poland and Soviet Ukraine at the end of World War II was based on a treaty signed on 9 September 1944 by the Ukrainian SSR with the newly-formed Polish Committee of National Liberation (PKWN). The exchange stipulated the transfer of ethnic Ukrainians to the Ukrainian SSR and of ethnic Poles and Jews who had Polish citizenship before September 17, 1939 (date of the Soviet Invasion of Poland) to post-war Poland, in accordance with the resolutions of the Yalta and Tehran conferences and the plans about the new Poland–Ukraine border.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/International_use_of_the_U.S._dollar">International use of the U.S. dollar</a></td>
      <td>The United States dollar was established as the world's foremost reserve currency by the Bretton Woods Agreement of 1944. It claimed this status from the British pound sterling after the devastation of two world wars and the massive spending of Great Britain's gold reserves.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Credit_card">Credit card</a></td>
      <td>A credit card is a payment card issued to users (cardholders) to enable the cardholder to pay a merchant for goods and services based on the cardholder's accrued debt (i.e., promise to the card issuer to pay them for the amounts plus the other agreed charges). The card issuer (usually a bank or credit union) creates a revolving account and grants a line of credit to the cardholder, from which the cardholder can borrow money for payment to a merchant or as a cash advance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Departure_tax">Departure tax</a></td>
      <td>A departure tax is a fee charged (under various names) by a country when a person is leaving the country.\n\n\n== Background ==\n\nSome countries charge a departure tax only when a person is leaving by air.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/FSB_Academy">FSB Academy</a></td>
      <td>The FSB Academy (Russian: Академия ФСБ), in full the Academy of the Federal Security Service of the Russian Federation (Russian: Академия федеральной службы безопасности Российской Федерации), is an education and research institution federally chartered to prepare Russian intelligence personnel for the Federal Security Service in particular and for the Russian Intelligence Community in general.\nThe academy was formed by presidential decree on August 24, 1992 on the foundation of the Higher School of the KGB, and is located in Michurinsky Prospekt, Moscow, Russia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_rights">Human rights</a></td>
      <td>Human rights are moral principles or norms for certain standards of human behaviour and are regularly protected in municipal and international law. They are commonly understood as inalienable, fundamental rights "to which a person is inherently entitled simply because she or he is a human being" and which are "inherent in all human beings", regardless of their age, ethnic origin, location, language, religion, ethnicity, or any other status.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_extinction">Human extinction</a></td>
      <td>Human extinction is the hypothetical end of the human species due to either natural causes such as population decline due to sub-replacement fertility, an asteroid impact or large-scale volcanism, or anthropogenic (human) causes, also known as omnicide.   For the latter, some of the many possible contributors include climate change, global nuclear annihilation, biological warfare and ecological collapse.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2008_Mumbai_attacks">2008 Mumbai attacks</a></td>
      <td>The 2008 Mumbai attacks (also referred to as 26/11, pronounced "twenty six eleven") were a series of terrorist attacks that took place in November 2008, when 10 members of Lashkar-e-Taiba, an Islamist terrorist organisation from Pakistan, carried out 12 coordinated shooting and bombing attacks lasting four days across Mumbai. The attacks, which drew widespread global condemnation, began on Wednesday 26 November and lasted until Saturday 29 November 2008.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Complication_(medicine)">Complication (medicine)</a></td>
      <td>A complication in medicine, or medical complication, is an unfavorable result of a disease, health condition, or treatment. Complications may adversely affect the prognosis, or outcome, of a disease.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>MERIT MEDICAL SYSTEMS INC      Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>Our business, <font color="blue">operations</font> and <font color="blue">financial condition</font> are subject to certain     risks and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>Should one or more of these risks or <font color="blue">uncertainties</font>     <font color="blue">materialize</font>, or should any <font color="blue">underlying assumptions prove</font> incorrect, our     actual results will vary, and <font color="blue">may vary materially from</font> those anticipated,     estimated, projected or expected</td>
    </tr>
    <tr>
      <td>Among the key factors that may have a     direct bearing on our business, <font color="blue">operations</font> or <font color="blue">financial condition</font> are the     factors identified below:         Our <font color="blue">products may</font> be subject to recall or <font color="blue">product liability</font> claims</td>
    </tr>
    <tr>
      <td>Our products are used in <font color="blue"><font color="blue">connection with</font> invasive procedures</font> and in other     <font color="blue">medical contexts</font> in which it is important that those <font color="blue">products function with</font>     precision and accuracy</td>
    </tr>
    <tr>
      <td>If our products do not <font color="blue">function as designed</font>, or are     <font color="blue">designed improperly</font>, we may choose to or be <font color="blue">forced by <font color="blue">regulatory</font> agencies</font> to     <font color="blue">withdraw <font color="blue">such products</font> from</font> the market</td>
    </tr>
    <tr>
      <td>In addition, if <font color="blue">medical personnel</font>     or their <font color="blue">patients suffer injury as</font> a result of any failure our products to     <font color="blue">function as designed</font>, or an <font color="blue">inappropriate design</font>, we could be subject to     <font color="blue">lawsuits seeking <font color="blue">significant</font> compensatory</font> and <font color="blue">punitive damages</font></td>
    </tr>
    <tr>
      <td>Any product     recall or <font color="blue">lawsuit seeking <font color="blue">significant</font> monetary damages may</font> have a material     adverse effect on our business, <font color="blue">operations</font> or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>14     ______________________________________________________________________         <font color="blue">Substantially </font>all of our products are <font color="blue">backed by</font> a limited warranty for     <font color="blue">returns due</font> to defects in quality and workmanship</td>
    </tr>
    <tr>
      <td>We maintain a reserve     for these future returned products, but the <font color="blue">actual costs</font> of <font color="blue">such returns may</font>     <font color="blue"><font color="blue">significant</font>ly exceed</font> the reserve, which could have a material adverse effect     on our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">Termination  </font>of  <font color="blue"><font color="blue">relationship</font>s</font>  with our suppliers, or failure of such     suppliers to perform, could disrupt our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on raw materials</font>, component parts, finished products, and services     <font color="blue">supplied by outside third parties</font> in <font color="blue">connection with</font> our business</td>
    </tr>
    <tr>
      <td>For     example,  <font color="blue">substantially</font>  all  of  our products are <font color="blue">sterilized by</font> a few     entities</td>
    </tr>
    <tr>
      <td>In addition, some of our products are <font color="blue"><font color="blue">manufacture</font>d</font> or assembled     <font color="blue">by third parties</font></td>
    </tr>
    <tr>
      <td>If a supplier of <font color="blue">significant</font> raw materials, component     parts, finished goods or services were to terminate its <font color="blue">relationship</font> with     us, or otherwise cease supplying raw materials, component parts, finished     goods or services <font color="blue">consistent</font> with past practice, our ability to meet our     <font color="blue">obligations</font>  to our end customers may be disrupted</td>
    </tr>
    <tr>
      <td>A <font color="blue"><font color="blue">disruption</font> with</font>     respect to <font color="blue">numerous products</font>, or <font color="blue">with respect</font> to a few <font color="blue">significant</font> products,     could  have  a  material adverse effect on our business, <font color="blue">operations</font> or     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We may be unable to protect our <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font></font> or <font color="blue">may infringe on</font>     the <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font></font> of others</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">remain competitive</font> is <font color="blue">dependent</font>, in part, upon our ability to     prevent other <font color="blue">companies from using</font> our <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font></font> incorporated     into our products</td>
    </tr>
    <tr>
      <td>We seek to protect our <font color="blue"><font color="blue">technology</font> through</font> a <font color="blue">combination</font>     of patents, trademarks, and trade secrets, as well as licenses, <font color="blue">proprietary</font>     know-how and <font color="blue">confidentiality agreements</font></td>
    </tr>
    <tr>
      <td>We may be unable, however, to     <font color="blue">prevent others</font> from using our <font color="blue">proprietary</font> information, or continue to use     such information itself, for <font color="blue">numerous reasons</font>, including the following,     which  could have a material adverse effect on the Company’s business,     <font color="blue">operations</font> or <font color="blue">financial condition</font>:         •      Our <font color="blue">issued patents may</font> not be <font color="blue">sufficiently broad</font> to <font color="blue">prevent others</font>     <font color="blue">from copying</font> our <font color="blue">proprietary</font> <font color="blue">technologies</font>;         •      Our <font color="blue">issued patents may</font> be challenged <font color="blue">by third parties</font> and deemed to     be overbroad or unenforceable;         •      Our <font color="blue">products may</font> infringe on the patents of others, requiring us to     alter or <font color="blue">discontinue</font> our <font color="blue">manufacture</font> or sale of <font color="blue">such products</font>;         •      Costs <font color="blue">associated with seeking enforcement</font> of our <font color="blue">patents against</font>     <font color="blue">infringement</font>, or <font color="blue">defending four self against allegations</font> of <font color="blue">infringement</font>,     may be <font color="blue">significant</font>;         •       Our <font color="blue">pending patent applications may</font> not be granted for various     reasons, including overbreadth or <font color="blue">conflict with</font> an <font color="blue">existing patent</font>; and         •      Other persons may in<font color="blue">dependent</font>ly develop, or have developed, similar     or superior <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We may be unable to successfully <font color="blue">manage growth</font>, particularly if accomplished     <font color="blue">through <font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Successful </font><font color="blue">implementation</font> of our business <font color="blue">strategy will</font> require that we     <font color="blue">effectively manage</font> any <font color="blue">associated growth</font></td>
    </tr>
    <tr>
      <td>To <font color="blue">manage growth</font> effectively, our     <font color="blue"><font color="blue">management</font> will</font> need to continue to implement changes in <font color="blue">certain aspects</font> of     our business, to improve our information systems and <font color="blue">operations</font> to respond     to  <font color="blue">increased demand</font>, to attract and retain <font color="blue">qualified personnel</font> and to     develop, train and manage an increasing number of <font color="blue">management</font>-level and other     employees</td>
    </tr>
    <tr>
      <td>Growth could place an increasing strain on our <font color="blue">management</font>,     financial, product design, marketing, distribution and other resources, and     we could experience operating <font color="blue">difficulties</font></td>
    </tr>
    <tr>
      <td>Any failure to <font color="blue">manage growth</font>     effectively  could  have  a  material adverse effect on our results of     <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>To the extent that we grow through <font color="blue">acquisition</font>, we will face the <font color="blue">additional</font>     <font color="blue">challenges</font> of <font color="blue">integrating</font> our current <font color="blue">operations</font>, culture, <font color="blue">informational</font>     <font color="blue">management</font> systems and other <font color="blue">characteristics with</font> that of the acquired     entity</td>
    </tr>
    <tr>
      <td>We may incur <font color="blue">significant</font> expenses in <font color="blue">connection with</font> negotiating     and  <font color="blue">consummating one</font> or more <font color="blue">transactions</font>, and we <font color="blue">may inherit certain</font>     <font color="blue">liabilities</font> in <font color="blue">connection with</font> the <font color="blue">acquisition</font> as a result of our failure or     <font color="blue">inability</font> to <font color="blue">conduct adequate due diligence</font> or otherwise</td>
    </tr>
    <tr>
      <td>In addition, we     may  not  realize  competitive advantages, synergies or other benefits     anticipated in <font color="blue">connection with</font> such <font color="blue">acquisition</font>(s)</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">adequately</font>     identify targets for, or <font color="blue">manage issues</font> related to its future <font color="blue">acquisition</font>s,     such <font color="blue">acquisition</font>s may have a <font color="blue">negative adverse</font> effect on our business and     financial results</td>
    </tr>
    <tr>
      <td>15     ______________________________________________________________________         A  <font color="blue">significant</font> adverse change in, or failure to <font color="blue">comply with</font>, governing     <font color="blue">regulations <font color="blue">could <font color="blue">adversely affect</font></font></font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of our products are “devices,” as defined in the Federal     Food, Drug and Cosmetic Act, (“FDA”) and the <font color="blue">manufacture</font>, distribution,     record keeping, labeling and <font color="blue">advertisement</font> of our products are subject to     <font color="blue">regulation by</font> the <font color="blue">FDA in the <font color="blue">United States </font></font>and its equivalent <font color="blue">regulatory</font>     agencies  in  various  foreign  countries  in  which  our products are     <font color="blue"><font color="blue">manufacture</font>d</font>, <font color="blue">distributed</font>, labeled, offered and sold</td>
    </tr>
    <tr>
      <td>Further, we are     subject  to  continual  review and <font color="blue">periodic inspections at</font> our current     facilities <font color="blue">with respect</font> to the FDA’s Quality System Regulations and similar     <font color="blue">requirements</font> of foreign countries</td>
    </tr>
    <tr>
      <td>In addition, we are subject to certain     <font color="blue">export control restrictions governed by</font> the <font color="blue">US Department of the Treasury     </font>and  may  be  governed by other <font color="blue">regulatory</font> agencies in various foreign     countries in which products are exported</td>
    </tr>
    <tr>
      <td>Our business, <font color="blue">operations</font> or     <font color="blue">financial condition</font> could be <font color="blue"><font color="blue">adversely affect</font>ed</font> if we are found to be out of     <font color="blue">compliance with governing regulations</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">such regulations</font> are amended to     become more <font color="blue">restrictive</font> and costly to <font color="blue">comply with</font>, the costs of compliance     <font color="blue">could <font color="blue">adversely affect</font></font> our business, <font color="blue">operations</font> or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our revenues are <font color="blue">derived from</font> a <font color="blue">few products</font> and     procedures</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our revenues are <font color="blue">attributable</font> to sales of our     <font color="blue">inflation devices</font></td>
    </tr>
    <tr>
      <td>During the year ended <font color="blue">December </font>31, 2005, sales of our     <font color="blue">inflation devices</font> (including <font color="blue">inflation devices</font> sold in <font color="blue">custom kits</font> and     through OEM channels) accounted for approximately 33prca our <font color="blue">total revenues</font></td>
    </tr>
    <tr>
      <td>Any material decline in <font color="blue">market demand</font> for our <font color="blue">inflation devices</font> could have     an adverse effect on our business, <font color="blue">operations</font> or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>In  addition,  the  products that have accounted for a majority of our     <font color="blue">historical revenues</font> are designed for use in <font color="blue">connection with</font> a few related     <font color="blue">medical procedures</font>, including angioplasty, stent placement procedures, and     <font color="blue">spinal procedures</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">subsequent <font color="blue">development</font>s</font> in <font color="blue">medical <font color="blue">technology</font></font> or drug     therapy make such procedures obsolete, or alter the <font color="blue">methodology</font> of such     procedures  so  as to eliminate the usefulness of our products, we may     experience a material decrease in demand for our products and experience     <font color="blue">deteriorating financial performance</font></td>
    </tr>
    <tr>
      <td>We may be unable to compete in our markets, particularly if there is a     <font color="blue">significant</font> change in <font color="blue">relevant practices</font> and <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>The  market  for  each of our products is <font color="blue">highly competitive</font></td>
    </tr>
    <tr>
      <td>We face     <font color="blue">competition</font>  from  many  companies,  many  of which are larger, better     established and have greater financial, technical and other resources and     <font color="blue">greater market presence than</font> we do</td>
    </tr>
    <tr>
      <td>Such resources and <font color="blue">market presence may</font>     enable our <font color="blue">competition</font> to more <font color="blue">effectively market competing products</font> or to     <font color="blue">market competing products at reduced prices</font> in order to <font color="blue">gain market</font> share</td>
    </tr>
    <tr>
      <td>In addition, our ability to <font color="blue">compete successfully</font> is <font color="blue">dependent</font>, in part, upon     our response to changes in <font color="blue">technology</font> and to our efforts to develop and     <font color="blue">market new products which</font> achieve <font color="blue">significant</font> market acceptance</td>
    </tr>
    <tr>
      <td><font color="blue">Competing     </font>companies with <font color="blue">substantially</font> greater resources than us are actively engaged     in  research and <font color="blue">development</font> of <font color="blue">diagnostic</font> and <font color="blue">interventional methods</font>,     <font color="blue">treatments</font> and procedures that <font color="blue">could limit</font> the market for our products and     <font color="blue">eventually</font> make <font color="blue">certain products obsolete</font></td>
    </tr>
    <tr>
      <td>A reduction in the demand for a     <font color="blue">significant</font> number of our products, or a few key products, could have a     material adverse effect on our business, <font color="blue">operations</font> or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> has been, and <font color="blue">may continue</font> to be,     volatile</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> has been, and <font color="blue">may continue</font> to be,     <font color="blue">highly volatile</font> for <font color="blue">various reasons</font>, including the following, which could     have a material adverse effect on the Company’s business, <font color="blue">operations</font> or     <font color="blue">financial condition</font>:         •      Our <font color="blue">announcement</font> of new products or <font color="blue">technical innovations</font>, or similar     <font color="blue">announcement</font>s by our <font color="blue">competitors</font>;         •       <font color="blue">Development  </font>of  new  procedures  that use, or do not use, our     <font color="blue">technology</font>;         •      Quarter-to-quarter variances in our financial results;         •       <font color="blue">Claims  </font>involving  potential <font color="blue">infringement</font> of patents and other     <font color="blue">intellectual property rights</font>;                                           16     ______________________________________________________________________         •      Analysts’ and other <font color="blue">projections</font> or <font color="blue">recommendations</font> regarding our     <font color="blue">common stock</font> or <font color="blue">medical <font color="blue">technology</font></font> stocks <font color="blue">generally</font>;         •      Any <font color="blue">restatement</font> of our <font color="blue">financial statements</font> or any <font color="blue">investigation</font> of     us by the SEC or another <font color="blue">regulatory</font> authority; and         •      A <font color="blue">general decline</font>, or rise, of <font color="blue">stock prices</font> in the <font color="blue">capital markets</font>     <font color="blue">generally</font></td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font> in <font color="blue">Euro and GBP </font><font color="blue">exchange rates may negatively impact</font> our     financial results</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in the rate of <font color="blue">exchange between</font> the <font color="blue">Euro and GBP </font>relative to     value of the US Dollar could have a <font color="blue">negative impact on</font> our margins and     financial results</td>
    </tr>
    <tr>
      <td>For example, during 2005, the <font color="blue">exchange rate between</font> the     <font color="blue">Euro and the US Dollar </font>resulted in an increase in our gross revenues of     approximately dlra263cmam000 and 0dtta09prca in gross profit</td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31, 2005, approximately dlra20dtta0 million, or 12dtta0prca,     of our sales were <font color="blue">denominated</font> in <font color="blue">Euros and GBP </font> If the rate of exchange     between <font color="blue">the Euro and the GBP </font>declines, against the US Dollar, we may not     be able to increase the prices we charge our European customers for products     <font color="blue">whose prices</font> are <font color="blue">denominated</font> in <font color="blue">Euros and GBP </font> Furthermore, we may be     unable or elect not to enter into hedging <font color="blue">transactions</font> which could mitigate     the  effect  of <font color="blue">declining exchange rates</font></td>
    </tr>
    <tr>
      <td>As a result, as the rate of     <font color="blue">exchange between</font> <font color="blue">Euros and GBP </font>declines, against the US Dollars, our     financial results may be <font color="blue">negatively impacted</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent</font> upon key personnel</td>
    </tr>
    <tr>
      <td>Our success is <font color="blue">dependent</font> on key <font color="blue">management</font> personnel, including Fred P     Lampropoulos, our Chairman of the Board, President and Chief Executive     Officer</td>
    </tr>
    <tr>
      <td><font color="blue">Lampropoulos </font>is not subject to any <font color="blue">agreement prohibiting</font> his     <font color="blue">departure</font>, and the Company does not maintain <font color="blue">key man life insurance on</font> his     life</td>
    </tr>
    <tr>
      <td>Lampropoulos, or of certain other key <font color="blue">management</font>     personnel, could <font color="blue">materially <font color="blue">adversely affect</font></font> our business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our success also depends, among other factors, on the <font color="blue">successful recruitment</font>     and retention of key <font color="blue">operations</font>, <font color="blue">manufacturing</font>, sales and other personnel</td>
    </tr>
    <tr>
      <td>We are subject to work stoppage, <font color="blue">transportation</font> and related risks</td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> products at various locations in the <font color="blue">United States </font>and in     <font color="blue">Ireland  </font>and  sell  our  products worldwide</td>
    </tr>
    <tr>
      <td>We depend on third-party     <font color="blue"><font color="blue">transportation</font> companies</font> to deliver <font color="blue">supplies necessary</font> to <font color="blue">manufacture</font> <font color="blue">Merit     </font>products from vendors to our <font color="blue">various facilities</font> and to move our products to     customers, operating divisions and other <font color="blue">subsidiaries located worldwide</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">manufacturing</font> <font color="blue">operations</font>, and the <font color="blue">operations</font> of the <font color="blue"><font color="blue">transportation</font> companies</font>     on  which we depend, may be <font color="blue"><font color="blue">adversely affect</font>ed</font> by natural disasters or     <font color="blue">significant</font> human events, such as a war, terrorist attack, riot, strike,     slowdown  or  similar  event</td>
    </tr>
    <tr>
      <td>Any <font color="blue">disruption</font> in our <font color="blue">manufacturing</font> or     <font color="blue">transportation</font>  could  <font color="blue">materially <font color="blue">adversely affect</font></font> our ability to meet     <font color="blue">customer demands</font> or our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Limits <font color="blue"><font color="blue">on reimbursement</font> imposed by governmental</font> and other <font color="blue">programs may</font>     <font color="blue">adversely affect</font> our business</td>
    </tr>
    <tr>
      <td>The cost of a <font color="blue">significant</font> portion of <font color="blue">medical care</font> is <font color="blue">funded by governmental</font>,     social  security or other <font color="blue">insurance programs</font></td>
    </tr>
    <tr>
      <td>Limits <font color="blue">on reimbursement</font>     imposed by such <font color="blue">programs may</font> <font color="blue">adversely affect</font> the ability of hospitals and     others to purchase our products</td>
    </tr>
    <tr>
      <td>In addition, limitations <font color="blue">on reimbursement</font>     for <font color="blue">procedures which utilize</font> our products <font color="blue">could <font color="blue">adversely affect</font></font> sales</td>
    </tr>
  </tbody>
</table>